{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:50:15Z","timestamp":1792349415604,"version":"4.4.0"},"reference-count":13,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA059483"],"award-info":[{"award-number":["R01DA059483"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA061265"],"award-info":[{"award-number":["R01DA061265"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jeanann Gray Dunlap Foundation"},{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["UM1TR004360"],"award-info":[{"award-number":["UM1TR004360"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sublingual buprenorphine for opioid use disorder (OUD) is indicated as a once-daily medication during stabilization and long-term treatment, yet patients may engage in \u201csplit dosing,\u201d dividing the daily dose into multiple administrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This secondary analysis examined buprenorphine dosing patterns among 165 stable non-pregnant outpatients with OUD and assessed concordance between patient-reported dosing and provider documentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients had been taking buprenorphine for a median of 16\u2009months (range 1-78). Most patients reported 2- (n\u2009=\u200963, 38.2%) or 3-times- (n\u2009=\u200974, 44.8%) daily dosing. A Cohen\u2019s kappa analysis revealed substantial agreement (\u03ba\u2009=\u20090.604,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001) between patient self-report and clinical documentation. Patient-reported buprenorphine total daily doses were higher and chronic pain comorbidities more common among patients splitting their dose than once-daily dosing patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results characterize sublingual buprenorphine dosing frequencies among outpatients with OUD and highlight real-world divergence from Food and Drug Administration labeling among patients stabilized on buprenorphine, indicating the need for evidence-based, patient-centered dosing strategies in OUD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342261492538","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:33:07Z","timestamp":1792067587000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing Buprenorphine Dosing Frequency During Outpatient Medication Treatment For Opioid Use Disorder"],"prefix":"10.1177","author":[{"given":"Phoebe","family":"Dacha","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Eglovitch","sequence":"additional","affiliation":[{"name":"Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Melmer","sequence":"additional","affiliation":[{"name":"Division of Addiction Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-458X","authenticated-orcid":false,"given":"Caitlin E.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Addiction Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-5395","authenticated-orcid":false,"given":"Madison M.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_3_3_3_2","volume-title":"SUBOXONE Package Insert","author":"Indivior","year":"2021","unstructured":"Indivior. SUBOXONE Package Insert. Indivior; 2021."},{"key":"e_1_3_3_4_2","volume-title":"ZUBSOLV Package Insert","author":"Orexo","year":"2025","unstructured":"Orexo. ZUBSOLV Package Insert. Orexo; 2025."},{"key":"e_1_3_3_5_2","volume-title":"Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP20-02-01-006","author":"SAMHSA","year":"2020","unstructured":"SAMHSA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP20-02-01-006. SAMHSA; 2020."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_3_3_7_2","unstructured":"ASAM. ASAM National Practice Guideline for the Treatment of Opioid Use Disorder\u20142020 Focused Update. ASAM; 2020. Accessed July 24 2026. https:\/\/www.asam.org\/Quality-Science\/quality\/2020-national-practice-guideline"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.035"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.70022"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13267"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209209"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/29767342241261562"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1244156"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurosci6020048"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261492538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261492538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261492538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:16:38Z","timestamp":1792347398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261492538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":13,"alternative-id":["10.1177\/29767342261492538"],"URL":"https:\/\/doi.org\/10.1177\/29767342261492538","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"29767342261492538"}}